Advertisement
Clinical Breast Cancer Home
Advanced searchSave search
Original Study| Volume 13, ISSUE 4, P239-246.e1, August 2013

Randomized Phase II Trial of Weekly vs. Every 2 Weeks vs. Every 3 Weeks Nanoparticle Albumin-Bound Paclitaxel With Bevacizumab as First-Line Chemotherapy for Metastatic Breast Cancer

DOI:https://doi.org/10.1016/j.clbc.2013.02.008
Randomized Phase II Trial of Weekly vs. Every 2 Weeks vs. Every 3 Weeks Nanoparticle Albumin-Bound Paclitaxel With Bevacizumab as First-Line Chemotherapy for Metastatic Breast Cancer
Previous ArticleCorrelation Between Nottingham Prognostic Index and Adjuvant! Online Prognostic Tools in Patients With Early-Stage Breast Cancer in Mid-Western Ireland
Next ArticlePrognostic Role of Human Epidermal Growth Factor Receptor 2 Status in Premenopausal Early Breast Cancer Treated With Adjuvant Tamoxifen

      Abstract

      Background

      Nanoparticle albumin-bound paclitaxel (nab-P) and bevacizumab have each demonstrated efficacy in patients with MBC. This trial was designed to further develop nab-P by evaluating its efficacy and safety using every 3 weeks (q3w), every 2 weeks (q2w), or weekly scheduling in combination with bevacizumab as first-line treatment of MBC.

      Patients and Methods

      This open-label phase II study randomized patients to nab-P 260 mg/m2 q3w (arm A) vs. 260 mg/m2 q2w with filgrastim (arm B) vs. 130 mg/m2 weekly uninterrupted, all with bevacizumab (15 mg/kg q3w arm A, 10 mg/kg q2w arms B and C). The primary endpoints were overall response rate (ORR) and toxicity. Time to tumor progression (TTP) and overall survival were secondary endpoints.

      Results

      Of 212 patients randomized, 208 (arm A, 75; arm B, 54; arm C, 79) were treated. Arm B was closed early due to toxicity, with more grade ≥ 2 fatigue (arm A, 46%; arm B, 62%; arm C, 62%) and bone pain (arm A, 11%; arm B, 23%; arm C, 5%). Neurotoxicity grade ≥ 2 was equivalent across the arms (> 50%) and reversible for most patients. Febrile neutropenia occurred in ≤ 3% of patients in all arms. ORR was similar among the arms (arm A, 45%; arm B, 41%; arm C, 46%). Median TTP was slightly longer in arm C (9.0 months) vs. arms A (8.0 months) and B (5.8 months) (overall, P = .105).

      Conclusions

      Significant antitumor activity was observed in all the arms. Weekly nab-P with bevacizumab appeared to have the highest therapeutic index. However, sensory neuropathy was treatment limiting, which suggests that a 3 weeks on and 1 week off schedule should be explored.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Breast Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Gradishar W.J.
        • Tjulandin S.
        • Davidson N.
        • et al.
        Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.
        J Clin Oncol. 2005; 23: 7794-7803
        View in Article
        • Ibrahim N.K.
        • Desai N.
        • Legha S.
        • et al.
        Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.
        Clin Cancer Res. 2002; 8: 1038-1044
        View in Article
        • Nyman D.W.
        • Campbell K.J.
        • Hersh E.
        • et al.
        Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies.
        J Clin Oncol. 2005; 23: 7785-7793
        View in Article
        • Gradishar W.J.
        • Krasnojon D.
        • Cheporov S.
        • et al.
        Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.
        J Clin Oncol. 2009; 27: 3611-3619
        View in Article
        • Blum J.L.
        • Savin M.A.
        • Edelman G.
        • et al.
        Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.
        Clin Breast Cancer. 2007; 7: 850-856
        View in Article
      6. Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival.
        Clin Breast Cancer. 2012; 12: 313-321
        View in Article
      7. Avastin® (bevacizumab) [prescibing information]. Genentech, South San Francisco, CA2012
        View in Article
        • Miller K.D.
        • Chap L.I.
        • Holmes F.A.
        • et al.
        Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
        J Clin Oncol. 2005; 23: 792-799
        View in Article
        • Miller K.
        • Wang M.
        • Gralow J.
        • et al.
        Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.
        N Engl J Med. 2007; 357: 2666-2676
        View in Article
        • Miles D.W.
        • Chan A.
        • Dirix L.Y.
        • et al.
        Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.
        J Clin Oncol. 2010; 28: 3239-3247
        View in Article
        • Robert N.J.
        • Dieras V.
        • Glaspy J.
        • et al.
        Ribbon-1: Randomized, double blind, placebo-controlled, phase II trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor-2 negative, locally recurrent or metastatic breast cancer.
        J Clin Oncol. 2011; 29: 1252-1260
        View in Article
        • Brufsky A.M.
        • Hurvitz S.
        • Perez E.
        • et al.
        RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.
        J Clin Oncol. 2011; 29: 4286-4293
        View in Article
        • Citron M.L.
        • Berry D.A.
        • Cirrincione C.
        • et al.
        Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup trial C9741/Cancer and Leukemia Group B trial 9741.
        J Clin Oncol. 2003; 21: 1431-1439
        View in Article
        • Robert N.
        • Krekow L.
        • Stokoe C.
        • et al.
        Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study.
        Breast Cancer Res Treat. 2011; 125: 115-120
        View in Article
        • McArthur H.L.
        • Rugo H.
        • Nulsen B.
        • et al.
        A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer.
        Clin Cancer Res. 2011; 17: 3398-3407
        View in Article
        • Volk L.D.
        • Flister M.J.
        • Chihade D.
        • et al.
        Synergy of nab-paclitaxel and bevacizumab in eradicating large orthotopic breast tumors and preexisting metastases.
        Neoplasia. 2011; 13: 327-338
        View in Article
        • Therasse P.
        • Arbuck S.G.
        • Eisenhauer E.A.
        • et al.
        New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
        J Natl Cancer Inst. 2000; 92: 205-216
        View in Article
        • Seidman A.D.
        • Berry D.
        • Cirrincione C.
        • et al.
        Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.
        J Clin Oncol. 2008; 26: 1642-1649
        View in Article
        • Verrill M.W.
        • Lee J.
        • Cameron D.A.
        • et al.
        Anglo-Celtic IV: first results of a UK National Cancer Research Network randomized phase III pharmacogenetic trial of weekly compared to 3 weekly paclitaxel in patients with locally advanced or metastatic breast cancer (ABC).
        J Clin Oncol. 2007; 25 (abstract LBA1005)
        View in Article
        • Insa A.
        • Lluch A.
        • Prosper F.
        • et al.
        Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients.
        Breast Cancer Res Treat. 1999; 56: 67-78
        View in Article
        • Koenders P.G.
        • Beex L.V.
        • Kloppenborg P.W.
        • et al.
        Human breast cancer: survival from first metastasis. Breast Cancer Study Group.
        Breast Cancer Res Treat. 1992; 21: 173-180
        View in Article
        • Imkampe A.
        • Bendall S.
        • Bates T.
        The significance of the site of recurrence to subsequent breast cancer survival.
        Eur J Surg Oncol. 2007; 33: 420-423
        View in Article
        • Danso M.A.
        • Blum J.L.
        • Robert N.J.
        • et al.
        Phase II trial of weekly nab-paclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancer.
        J Clin Oncol. 2008; 26 (1075 (abstract))
        View in Article
        • Mirtsching B.
        • Cosgriff T.
        • Harker G.
        • et al.
        A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer.
        Clin Breast Cancer. 2011; 11: 121-128
        View in Article
        • Roy V.
        • LaPlant B.R.
        • Gross G.G.
        • et al.
        Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531).
        Ann Oncol. 2009; 20: 449-453
        View in Article
        • Schwartzberg L.S.
        • Arena F.P.
        • Mintzer D.M.
        • et al.
        Phase II multicenter trial of albumin-bound paclitaxel and capecitabine in first-line treatment of patients with metastatic breast cancer.
        Clin Breast Cancer. 2012; 12: 87-93
        View in Article
        • Rugo H.S.
        • Barry W.T.
        • Moreno-Aspitia A.
        • et al.
        CALGB 40502/NCCTG N063H: randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC).
        J Clin Oncol. 2012; 30 (abstract).: 1002
        View in Article

      Article info

      Publication history

      Accepted: February 26, 2013
      Received: November 27, 2012

      Identification

      DOI: https://doi.org/10.1016/j.clbc.2013.02.008

      Copyright

      © 2013 Elsevier Inc. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX